AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19386052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (n=14)
Number of subjects: 36
Study 19386052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (n=22)
Number of subjects: 36
Study 19386052 — intervention group
Group type: COMPARATOR
Intervention: TV watching (n=14)
Number of subjects: 36
Study 19386052 — intervention group
Group type: COMPARATOR
Intervention: TV watching (n=22)
Number of subjects: 36
Study 17351187 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization
Number of subjects: 510
Study 17351187 — intervention group
Group type: COMPARATOR
Intervention: No coronary intervention before vascular surgery
Number of subjects: 510
Study 15203432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for six weekly one-hour sessions
Number of subjects: 61
Study 15203432 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (SP) for six weekly one-hour sessions
Number of subjects: 61
Study 11246324 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective gown and glove isolation
Number of subjects: 0
Study 11246324 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict handwashing
Number of subjects: 0
Study 11246324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gown and glove isolation
Number of subjects: 0
Study 11246324 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing compliance
Number of subjects: 0
Study 11246324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gowning and gloving compliance
Number of subjects: 0
Study 9935252 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin orally before surgery as a single dose
Number of subjects: 0
Study 9935252 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin orally before surgery as multiple doses
Number of subjects: 0
Study 7860441 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic administration of platelet concentrates
Number of subjects: 0
Study 7860441 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic administration of platelets
Number of subjects: 0
Study 3354496 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium from milk
Number of subjects: 13
Study 3354496 — intervention group
Group type: COMPARATOR
Intervention: Calcium from spinach
Number of subjects: 13
Study 3354496 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of calcium absorption
Number of subjects: 13
Study 31815770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion nanotechnology monitoring system with fuzzy logic alarm algorithm
Number of subjects: 0
Study 31815770 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 225
Study 30732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy of head and neck regions
Number of subjects: 225
Study 30732142 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic and education status
Number of subjects: 225
Study 30732142 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 225
Study 28824055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat® with a spacer (AeroChamber®)
Number of subjects: 18
Study 28824055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat® without a spacer
Number of subjects: 18
Study 28824055 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 18
Study 25355179 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN program
Number of subjects: 779
Study 25355179 — intervention group
Group type: COMPARATOR
Intervention: Healthy Teens (attention-control intervention)
Number of subjects: 779
Study 24022375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM)
Number of subjects: 624
Study 24022375 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPS practice model (VPM)
Number of subjects: 624
Study 24022375 — intervention group
Group type: COMPARATOR
Intervention: Control group (education of nursing home staff about dementia)
Number of subjects: 624
Study 21706518 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of vitamin D(3) per day
Number of subjects: 494
Study 21706518 — intervention group
Group type: COMPARATOR
Intervention: 2000 IU of vitamin D(3) per day
Number of subjects: 494
Study 21706518 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D(3) per day
Number of subjects: 494
Study 19798610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided transmural drainage (EUD)
Number of subjects: 60
Study 19798610 — intervention group
Group type: COMPARATOR
Intervention: Conventional transmural drainage (CTD)
Number of subjects: 60
Study 16848141 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (high conception risk phase)
Number of subjects: 2
Study 16848141 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 2
Study 16848141 — intervention group
Group type: EXPERIMENTAL
Intervention: First five days of the cycle (low estrogen level)
Number of subjects: 2
Study 16848141 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric facial traits
Number of subjects: 2
Study 15370099 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi fruit consumption (2 or 3 kiwi fruit per day for 28 days)
Number of subjects: 0
Study 15370099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10786740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine in 0.9% glucose
Number of subjects: 60
Study 10786740 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine in 8% glucose
Number of subjects: 60
Study 9574235 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually risk-adjusted follow-up programme
Number of subjects: 0
Study 9574235 — intervention group
Group type: COMPARATOR
Intervention: Controlled economic studies
Number of subjects: 0
Study 8324023 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg daily for 10 days)
Number of subjects: 101
Study 8324023 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin-clavulanic
Number of subjects: 101
Study 8324023 — intervention group
Group type: COMPARATOR
Intervention: erythromycin
Number of subjects: 101
Study 3567865 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 78
Study 3567865 — intervention group
Group type: COMPARATOR
Intervention: Control (transurethral resection only)
Number of subjects: 78
Study 30333922 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Performance Dashboard during monthly supervision
Number of subjects: 148
Study 30333922 — intervention group
Group type: COMPARATOR
Intervention: Standard monthly supervision without the Dashboard
Number of subjects: 148
Study 27427308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE) administered to 1341 residents (47% of eligible)
Number of subjects: 7682
Study 27427308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using MMSE
Number of subjects: 7682
Study 25018037 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone 1000 mg plus prednisone 5 mg by mouth twice daily
Number of subjects: 0
Study 25018037 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study 24054956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-control
Number of subjects: 2248
Study 24054956 — intervention group
Group type: COMPARATOR
Intervention: Rhythm-control
Number of subjects: 2248
Study 21914596 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive PROM stretching
Number of subjects: 15
Study 21914596 — intervention group
Group type: COMPARATOR
Intervention: Prolonged PROM stretching
Number of subjects: 15
Study 19120893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored eradication therapy (PPI/AC for CAM-sensitive strains, PPI/AM for CAM-resistant strains)
Number of subjects: 70
Study 19120893 — intervention group
Group type: COMPARATOR
Intervention: Control group (PPI/AC therapy)
Number of subjects: 70
Study 19120893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored eradication therapy for CAM-resistant strains
Number of subjects: 70
Study 16634738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for 6 weeks
Number of subjects: 897
Study 16634738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for 6 months
Number of subjects: 897
Study 16634738 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy (6 weeks or 6 months)
Number of subjects: 897
Study 12711662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling (3 sessions)
Number of subjects: 161
Study 12711662 — intervention group
Group type: COMPARATOR
Intervention: Group treatment (2 weeks + 4 out-patient sessions)
Number of subjects: 161
Study 10579608 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic alerting system
Number of subjects: 192
Study 10579608 — intervention group
Group type: COMPARATOR
Intervention: Control (no automatic notification)
Number of subjects: 192
Study 8923126 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice a day)
Number of subjects: 5732
Study 8923126 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (Fluoxetine 20 mg once a day and Fluvoxamine 100 mg twice a day)
Number of subjects: 5732
Study 8923126 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 5732
Study 8923126 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 5732
Study 1673110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (b.i.d.)
Number of subjects: 32
Study 1673110 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (b.i.d.)
Number of subjects: 32
Study 1673110 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg (b.i.d.)
Number of subjects: 32
Study 1673110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6779652 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective hyperalimentation
Number of subjects: 50
Study 6779652 — intervention group
Group type: COMPARATOR
Intervention: Standard hyperalimentation
Number of subjects: 50
Study 31295270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (Monitor+Accept)
Number of subjects: 0
Study 31295270 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness training (Monitor Only)
Number of subjects: 0
Study 31295270 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 31295270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mindfulness interventions (Monitor+Accept and Monitor Only)
Number of subjects: 0
Study 28423524 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m2 for 12 weeks)
Number of subjects: 115
Study 26426352 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg)
Number of subjects: 27
Study 26426352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg)
Number of subjects: 27
Study 26426352 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + Cilostazol
Number of subjects: 27
Study 26426352 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 27
Study 24858885 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Healthy Together (GHT) intervention
Number of subjects: 48
Study 22227457 — intervention group
Group type: EXPERIMENTAL
Intervention: Generate condition
Number of subjects: 49
Study 22227457 — intervention group
Group type: COMPARATOR
Intervention: Read condition
Number of subjects: 49
Study 19642225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of continuous complex fractionated atrial electrograms (CFEs) in the left atrium/coronary sinus
Number of subjects: 60
Study 19642225 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) plus linear ablation without additional ablation of CFEs
Number of subjects: 60
Study 17403225 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular duct relocation plus excision of the sublingual glands
Number of subjects: 100
Study 17403225 — intervention group
Group type: COMPARATOR
Intervention: Submandibular duct relocation
Number of subjects: 100
Study 17403225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 100
Study 11108069 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder within three days of ED attendance
Number of subjects: 400
Study 11108069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone call reminder)
Number of subjects: 400
Study 9344199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination clindamycin/benzoyl peroxide gel
Number of subjects: 334
Study 9344199 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin gel
Number of subjects: 334
Study 9344199 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide gel
Number of subjects: 334
Study 9344199 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 334
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million units of recombinant alpha‐2a‐interferon subcutaneously, thrice weekly, for six months
Number of subjects: 32
Study 8384978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-treated responders
Number of subjects: 32
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated patients
Number of subjects: 32
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 32
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 32
Study 8384978 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapy follow-up
Number of subjects: 32
Study 3099273 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate
Number of subjects: 17
Study 28618046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle care intervention group (n=58)
Number of subjects: 114
Study 28618046 — intervention group
Group type: COMPARATOR
Intervention: Routine nurse control group (n=56)
Number of subjects: 114
Study 27456379 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qigong exercise (20-min twice daily for 21 days)
Number of subjects: 108
Study 27456379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special exercise intervention)
Number of subjects: 108
Study 25172376 — intervention group
Group type: COMPARATOR
Intervention: Benzathine benzylpenicillin
Number of subjects: 508
Study 25172376 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (pooled)
Number of subjects: 508
Study 25172376 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily co-trimoxazole for 3 days
Number of subjects: 508
Study 25172376 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily co-trimoxazole for 5 days
Number of subjects: 508
Study 23740801 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ocrelizumab
Number of subjects: 378
Study 23740801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg ocrelizumab
Number of subjects: 378
Study 23740801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ocrelizumab-treated groups
Number of subjects: 378
Study 23740801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 20803853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 0
Study 20803853 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 0
Study 18805718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants augmented with autogenous bone graft
Number of subjects: 20
Study 18805718 — intervention group
Group type: COMPARATOR
Intervention: Immediate implants augmented with synthetic bone graft
Number of subjects: 20
Study 16466172 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment for clearing heat, detoxicating and nourishing Yin (CHM)
Number of subjects: 115
Study 16466172 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of loratadine 10 mg once a day and ketotifen 1 mg once every night
Number of subjects: 115
Study 12833109 — intervention group
Group type: EXPERIMENTAL
Intervention: SCHO breakfast
Number of subjects: 26
Study 12833109 — intervention group
Group type: COMPARATOR
Intervention: CCHO breakfast
Number of subjects: 26
Study 10927729 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception to avoid exchanging call
Number of subjects: 221
Study 10927729 — intervention group
Group type: EXPERIMENTAL
Intervention: Misrepresenting a diagnosis in a medical record to protect patient privacy
Number of subjects: 221
Study 10927729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabricating a laboratory value to an attending physician
Number of subjects: 221
Study 10927729 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting their own urine in a drug test to protect a colleague
Number of subjects: 221
Study 10927729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying about checking a patient's stool for blood to cover up a medical mistake
Number of subjects: 221
Study 8777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 12
Study 8777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (10-20 mg/l blood levels)
Number of subjects: 12
Study 8777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cromoglycate
Number of subjects: 12
Study 8777828 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (as required)
Number of subjects: 12
Study 30114246 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of detemir (1.6 U/kg body weight)
Number of subjects: 10
Study 30114246 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of glargine (1.6 U/kg body weight)
Number of subjects: 10
Study 30114246 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine (1.6 U/kg body weight) during last 6 hours of the clamp
Number of subjects: 10
Study 26216048 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 0
Study 26216048 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 0
Study 23795552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic, visual-only exposure
Number of subjects: 0
Study 23795552 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual speech (inter-sensory redundancy)
Number of subjects: 0
Study 23234771 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo positive airway pressure (DuoPAP)
Number of subjects: 67
Study 23234771 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 67
Study 20634742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa-based protein and carbohydrate drink
Number of subjects: 7
Study 20634742 — intervention group
Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 7
Study 18479755 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic molecular resonance bipolar tonsillectomy (EMRBT)
Number of subjects: 800
Study 18479755 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 800
Study 18479755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 800
Study 15719743 — intervention group
Group type: EXPERIMENTAL
Intervention: Shennong Ganzhining (SG)
Number of subjects: 190
Study 15719743 — intervention group
Group type: COMPARATOR
Intervention: Zhibituo treatment
Number of subjects: 190
Study 12830408 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human drotrecogin alfa (activated) (DrotAA)
Number of subjects: 0
Study 12830408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11012953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (R 0.1)
Number of subjects: 3
Study 11012953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (R 0.2)
Number of subjects: 3
Study 11012953 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.2% (B 0.2)
Number of subjects: 3
Study 11012953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (R 0.1) and Ropivacaine 0.2% (R 0.2)
Number of subjects: 3
Study 8659471 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvold activator
Number of subjects: 42
Study 8659471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel function regulator
Number of subjects: 42
Study 8659471 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 1325321 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise for 4 minutes
Number of subjects: 10
Study 1325321 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled erythrocytes
Number of subjects: 10
Study 1325321 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In‐labelled platelets
Number of subjects: 10
Study 1325321 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In‐labelled granulocytes
Number of subjects: 10
Study 6401878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day)
Number of subjects: 604
Study 6401878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day) + Dipyridamole (225 mg/day)
Number of subjects: 604
Study 6401878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 6401878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day) and Aspirin (1 g/day) + Dipyridamole (225 mg/day) combined
Number of subjects: 604
Study 31686181 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 35
Study 31686181 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 35
Study 31000233 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines Daily Amount (GDA)
Number of subjects: 492
Study 31000233 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light System (TLS)
Number of subjects: 492
Study 31000233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Warnings
Number of subjects: 492
Study 30015676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day initiation regimen (single ALNCD injection + one 30-mg dose of oral aripiprazole on day 1)
Number of subjects: 161